Search clinical trials for: Alemtuzumab (GZ402673)

Total 458 results

The Cleveland Clinic
National Cancer Institute (NCI); University of Michigan

Completed

Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI); Genzyme, a Sanofi Company

Terminated

Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia

United States
Children's Hospital Medical Center, Cincinnati

Recruiting

Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation

Allogeneic Hematopoietic Cell Transplantation

United States
King Chulalongkorn Memorial Hospital
Bayer

Completed

The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL) (C+CHOP/ESHAP)

Peripheral T-cell Lymphoma

Thailand
Genzyme, a Sanofi Company

Completed

Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients

B-Cell Chronic Lymphocytic Leukemia

Sweden, United States, Croatia, Canada, Ukraine, Austria, Bulgaria, France, Germany, Greece, Italy, Poland, Portugal, Romania, Russian Federation
Versailles Hospital

Completed

Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4 (ALFA1401)

Acute Myeloid Leukemia

France
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Terminated

Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia (Mafia)

Fanconi Anemia | Severe Aplastic Anemia

United States
M.D. Anderson Cancer Center

Completed

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Genzyme, a Sanofi Company

Completed

Study of Safety and Efficacy of 6 mL Synvisc-One (Hylan G-F 20) in Indian Patients With Symptomatic Osteoarthritis of Knee(s) After Initial and Repeat Treatment (OASIS)

Osteoarthritis
Washington University School of Medicine

Recruiting

Immune Disorder HSCT Protocol

Severe Combined Immunodeficiency | Chronic Granulomatous Disease | DiGeorge Syndrome | Hemophagocytic Lymphohistiocytosis | Wiskott-Aldrich Syndrome | X-linked Lymphoproliferative Syndrome | X-linked Agammaglobulinemia | Chediak-Higashi Syndrome | IPEX | Autoimmune Lymphoproliferative Syndrome | Common Variable... and other conditions

United States
Washington University School of Medicine
HealthCore-NERI; Pediatric Blood and Marrow Transplant Consortium

Completed

Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia (URTH)

Severe Thalassemia

United States
German Cancer Research Center
University Hospital Heidelberg; University Hospital Dresden

Not yet recruiting

Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients With AML (GALAXY33)

Relapsed/Refractory Acute Myeloid Leukemia (AML)

Germany
Brown University
Pfizer; The Miriam Hospital; Rhode Island Hospital

Active, not recruiting

Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
New York Medical College

Completed

Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Baylor College of Medicine
The Methodist Hospital Research Institute

Terminated

Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1H

Graft Failure

United States
Baylor College of Medicine
The Methodist Hospital Research Institute

Terminated

Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases

Inherited Metabolic Storage Diseases

United States
Northwestern University
GlaxoSmithKline; National Comprehensive Cancer Network

Active, not recruiting

Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States, Sweden
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML

Acute Myeloid Leukemia

Italy
Baylor College of Medicine
Center for Cell and Gene Therapy, Baylor College of Medicine

Terminated

Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders (MASCI)

Severe Combined Immunodeficiency Disease | Severe Primary Immunodeficiency Disorder | Undefined T Cell Deficiency Disorder | Wiskott-Aldrick Syndrome

United States
Assistance Publique - Hôpitaux de Paris
Association pour l'Etude des Fonctions Digestives (AEFD)

Unknown

Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda

Porphyria Cutanea Tarda

France
Sanofi
National Institute on Aging (NIA)

Withdrawn

Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease

Dementia Alzheimer's Type

United States
Genzyme, a Sanofi Company

Completed

Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA (EMERALD)

Relapsing-remitting Multiple Sclerosis

Belgium, Spain, France, Netherlands
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia

Leukemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Lymphoma | Leukemia

United States
M.D. Anderson Cancer Center
Kura Oncology, Inc.

Not yet recruiting

A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
Eisai Inc.

Completed

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
David Rizzieri, MD
Miltenyi Biomedicine GmbH

Completed

Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath

Lymphoma | Leukemia | Solid Tumors | Myelodysplasia | Myeloma

United States
Royal Marsden NHS Foundation Trust

Completed

A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion

Chronic Lymphocytic Leukaemia
Mayo Clinic
National Cancer Institute (NCI)

Completed

Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia

Leukemia

United States
Pfizer

No longer available

Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy (AML)

CD33 Positive Acute Myelogenous Leukemia

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Alemtuzumab to Treat Severe Aplastic Anemia

Severe Aplastic Anemia, Refractory | Severe Aplastic Anemia, Relapse

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Terminated

Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML (MPDMDSBMT)

Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders

United States
David Rizzieri, MD
Miltenyi Biomedicine GmbH

Completed

Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath

Lymphoma | Leukemia | Solid Tumors | Myelodysplasia | Myeloma

United States
David Rizzieri, MD

Completed

Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes

Sickle Cell Anemia | Pure Red Cell Aplasia | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Severe Aplastic Anemia

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia

Leukemia, Myelocytic, Acute | Infusions, Intravenous
Sidney Kimmel Comprehensive Cancer Center at Johns...
StemlineTherapeutics, Inc.

Recruiting

Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML (GO-TAG)

Acute Myeloid Leukemia

United States
University of California, San Diego
Pfizer; Celgene Corporation

Completed

Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States
Hackensack Meridian Health

Completed

Stem Cell Transplantation for Sickle Cell Anemia

Sickle Cell Disease

United States
Oxford BioTherapeutics Ltd

Recruiting

Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

Solid Tumor

United States, Belgium, Spain, France, Greece
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H

Lymphoproliferative Disorders | Leukemia | Multiple Myeloma | Myelodysplastic Disorders | Plasma Cell Dyscrasia

United States
Dana-Farber Cancer Institute
Genzyme, a Sanofi Company

Completed

Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL

Chronic Lymphocytic Leukemia

United States
Northwestern University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Active, not recruiting

HLA-Identical Sibling Renal Transplant Tolerance

Kidney Transplantation | Graft Rejection | Immunosuppression

United States
University of California, San Diego
Genzyme, a Sanofi Company

Terminated

Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

Acute Myeloid Leukemia

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission

Leukemia, Myelocytic, Acute
Masonic Cancer Center, University of Minnesota

Terminated

Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis

Histiocytosis, Langerhans-cell

United States
Baylor College of Medicine
Center for Cell and Gene Therapy, Baylor College of Medicine; University of...

Terminated

Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT (RAFHAS)

FANCONI ANEMIA

United States
M.D. Anderson Cancer Center
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)

Leukemia

United States
Northwestern University
Bayer

Completed

A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL

Leukemia

United States
Mayo Clinic

Completed

Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Lymphocytic Leukemia

United States

Search clinical trials for: Alemtuzumab (GZ402673)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations